Drug Trial Radar · NCT06253871
A Phase 1/2 Study of IAM1363 in HER2 Cancers
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
463
Planned (sponsor's estimate)
Start
Mar 25, 2024
Primary completion
Oct 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Iambic Therapeutics, IncIndustry
- Sponsor type
- Industry
- First posted
- Feb 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2 open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Conditions
- HER2 Mutation-Related Tumors
- HER2
- HER2-positive Breast Cancer
- HER2 + Breast Cancer
- Brain Metastases From Solid Tumors
- Brain Metastases From HER2 and Breast Cancer
- CNS Metastases
- HER2-Positive Solid Tumors
- NSCLC (Non-small Cell Lung Cancer)
- HER2-positive Bladder Cancer
- HER2-positive Colorectal Cancer
- HER2 + Gastric Cancer
- HER2-positive Gastroesophageal Cancer
Interventions
IAM1363Drug
IAM1363 monotherapy
Oral treatment with IAM1363 capsules or tablets, administered in combination with capecitabine + trastuzumabDrug
Cohort 4A
Oral treatment with IAM1363 capsules or tablets, administered in combination with capecitabine + zanidatamabDrug
Cohort 4B
Oral treatment with IAM1363 capsules or tablets, administered in combination with T-DxdDrug
Cohort 4C
Oral treatment with IAM1363 capsules or tablets, administered in combination with pembrolizumab +/- carboplatin +/- pemetrexedDrug
Cohort 4D
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of dose limiting toxicities (DLTs) (Part 1 only)Time frame: 21 days
- Incidence and severity of adverse events (AEs)Time frame: Through 30 days after the last dose of study drug (up to 90 days for Cohort 4D)
- Pharmacokinetic (PK) parametersTime frame: Up to 42 days
- Confirmed objective response rate (cORR)Time frame: Through study completion, estimated as 57 months
- Confirmed central nervous system ORR (CNS-cORR)Time frame: Through study completion, estimated as 57 months
- Frequency of IAM1363 dose modifications, including treatment discontinuationsTime frame: Through 30 days after the last dose of study drug
- Incidence and severity of clinical laboratory abnormalitiesTime frame: Through 30 days post last dose of study drug
- Incidence of ECG abnormalitiesTime frame: Through 30 days after the last dose of study drug
Locations
53 sites in 8 countries. Site status is shown where the registry gives one.
UCSD Moores Cancer Center
La Jolla, California · Recruiting
USC Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
University of Colorado Cancer Center
Aurora, Colorado · Recruiting
University of Miami
Miami, Florida · Recruiting
Comprehensive Hematology Oncology
St. Petersburg, Florida · Recruiting
University of Chicago
Chicago, Illinois · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Henry Ford Cancer Institute
Detroit, Michigan · Recruiting
START - Midwest Cancer Research Center
Grand Rapids, Michigan · Recruiting
Saint Luke's Cancer Institute
Kansas City, Missouri · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Dartmouth Hitchcock Medical
Lebanon, New Hampshire · Recruiting
Rutgers Cancer Institute
New Brunswick, New Jersey · Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
Duke Cancer Institute
Durham, North Carolina · Recruiting
University Hospital Cleveland Medical Center
Cleveland, Ohio · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma · Recruiting
Providence Cancer Institute
Portland, Oregon · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Vanderbilt Ingram Cancer Center
Nashville, Tennessee · Recruiting
NEXT Oncology - Austin
Austin, Texas · Recruiting
Mary Crowley Cancer Research
Dallas, Texas · Recruiting
MD Anderson Cancer Center - University of Texas
Houston, Texas · Recruiting
START Mountain Region
West Valley City, Utah · Recruiting
NEXT Oncology - Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Centre Georges François Leclerc
Dijon, France · Recruiting
Institut de Cancerologie de l'Ouest
Saint-Herblain, France · Recruiting
Institut Universitaire du Cancer de Toulouse (IUCT) Oncopole Institut Claudius Regaud "
Toulouse, France · Recruiting
Cork University Hospital, Wilton
Cork, Ireland · Recruiting
St. Vincent's University Hospital
Dublin, Ireland · Recruiting
The START center Dublin
Dublin, Dublin, Ireland · Recruiting
Azienda Ospedaliero Universitaria Careggi - Largo Giovanni Alessandro Brambilla 3
Florence, Italy · Recruiting
Istituto Europeo di Oncologia (IEO)
Milan, Italy · Recruiting
Grande Ospedale Metropolitano Niguarda
Milan, Italy · Recruiting
Azienda Ospedaliera Universitaria Luigi Vanvitelli
Naples, Italy · Recruiting
Netherlands Cancer Institute-Antoni van Leeuwenhoek
Amsterdam, Netherlands · Recruiting
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.